GenoPredicta™ for Multiple Myeloma

About Predicta Biosciences

Predicta Biosciences is a private, venture-backed diagnostics company founded in 2018 and based in San Diego. The company has developed the GenoPredicta™ platform, a transformative cellular liquid biopsy that performs whole genome sequencing on circulating tumor cells and bone marrow samples to deliver superior sensitivity and genomic insights for multiple myeloma. With its first commercial product launched in April 2025 and a recent $23.4M funding round in October 2025, Predicta is positioned to scale its platform, challenge the current standard of care, and expand into broader hematological and autoimmune indications. The company is led by a seasoned team with deep expertise in genomics and oncology, supported by prominent scientific founders and investors.

Therapeutic Areas